https://www.selleckchem.com/pr....oducts/ro-61-8048.ht
In this review, we propose that such drugs could potentially restore NK cell activity allowing individuals to be more protective against COVID-19 infection and its complications. The aim was to examine the clinical characteristics and risk factors for bloodstream infection (BSI) due to carbapenem-resistant (CRKP) in patients with hematologic malignancies. A single-centre, retrospective case-control study representing 734 patients with hematologic malignancies between January 1, 2017, and December 31, 2018, was conducted. Demographic
Like
Comment
Share
